WO2022079250A1 - Composés pour le traitement d'infections virales - Google Patents

Composés pour le traitement d'infections virales Download PDF

Info

Publication number
WO2022079250A1
WO2022079250A1 PCT/EP2021/078628 EP2021078628W WO2022079250A1 WO 2022079250 A1 WO2022079250 A1 WO 2022079250A1 EP 2021078628 W EP2021078628 W EP 2021078628W WO 2022079250 A1 WO2022079250 A1 WO 2022079250A1
Authority
WO
WIPO (PCT)
Prior art keywords
syk inhibitor
pharmaceutically acceptable
solvate
hydrate
acceptable salt
Prior art date
Application number
PCT/EP2021/078628
Other languages
English (en)
Inventor
Ulrich Betz
Lars Burgdorf
Dirk Finsinger
Markus Klein
Sven Carsten POETZSCH
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of WO2022079250A1 publication Critical patent/WO2022079250A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • the present invention provides for the use of inhibitors of the kinase SYK (Spleen Tyrosine Kinase) in the treatment of coronavirus infections, including SARS-CoV infections such as COVID-19.
  • SYK Single Tyrosine Kinase
  • Syk spleen tyrosine kinase
  • spleen tyrosine kinase is a 72 kDa non-receptor tyrosine kinase that is expressed throughout the hematopoietic lineage, as well as in various other cell types ranging from fibroblasts, osteoclasts and hepatocytes to epithelial and neuronal cells (Mocsai, et al., Nat Rev Immunol. 2010; 10(6): 387-402).
  • Fc receptor signalling and B cell receptor signalling As a major regulator of both Fc receptor signalling and B cell receptor signalling, Syk plays a central role in the adaptive immune system.
  • Syk is involved in the regulation of diverse other cellular events, including cellular adhesion, innate immune recognition, osteoclast maturation, platelet activation and vascular development. More recently, it has been shown that Syk is also a promoter of cell survival in various cancer cell types.
  • Coronaviruses are positive-sense, single-stranded RNA (ssRNA) viruses of the order Nidovir ales, in the family Coronaviridae .
  • ssRNA single-stranded RNA
  • SARS-CoV-1 severe acute respiratory syndrome
  • MERS-CoV Middle East respiratory syndrome
  • COVID-19 SARS-CoV-2
  • SARS-CoV-2 closely resembles SARS-CoV-1, the causative agent of the SARS epidemic of 2002-03 (Fung, et al., Annu. Rev. Microbiol. 2019. 73:529-57). Severe disease has been reported in approximately 15% of patients infected with SARS-CoV-2, of which one third progress to critical disease (e.g. respiratory failure, shock, or multiorgan dysfunction (Siddiqi, et al., J. Heart and Lung Trans. (2020), doi: https://doi.Org/10.1016/j.healun.2020.03.012, Zhou, et al., Lancet 2020; 395: 1054-62.
  • critical disease e.g. respiratory failure, shock, or multiorgan dysfunction
  • the virus has a high transmission rate, likely linked to high early viral loads and lack of pre-existing immunity (He, et al., Nat Med 2020 https://doi.org/10.1038/s41591-020-0869-5). It causes severe disease especially in the elderly and in individuals with comorbidities.
  • the global burden of COVID- 19 is immense, and therapeutic approaches are increasingly necessary to tackle the disease.
  • Intuitive anti-viral approaches including those developed for enveloped RNA viruses like HIV- 1 (lopinavir plus ritonavir) and Ebola virus (remdesivir) have been implemented in testing as investigational drugs (Grein et al., NEJM 2020 https://doi.org/10.1056/NEJMoa2007016; Cao, et al., NEJM 2020 DOI: 10.1056/NEJMoa2001282).
  • Figure 1 shows the following: A) Representative images from dimethyl sulfoxide (DMSO)- resp. remdesivir-treated wells. Infected (arrow) and uninfected (arrowhead) cells are indicated; 500 pm and 50 pm scale bars are shown in the composite and magnified images, respectively. Raw and normalized (Norm.) values calculated from the images are shown. B) Box and whiskers plot of SARS-CoV-2 assay control ECsos obtained from independent biological experiments with mean indicated with a bar and all data points shown. Whiskers indicate minimums and maximums.
  • DMSO dimethyl sulfoxide
  • Figure 2 shows % infected cells (in blue), total cells per well in the HeLa-ACE2/SARS-CoV- 2 infection assay (in orange), and live cells per well in the uninfected HeLa-ACE2 counterscreen cytotoxicity assay (in magenta).
  • the invention provides Syk inhibitors for use in the treatment of viral infections in a subject in need thereof.
  • said treatment is an anti-viral treatment.
  • the viral infection is a single-strand RNA viral infection.
  • the viral infection is a coronavirus infection.
  • the viral infection is a SARS-CoV-1, MERS-CoV, or SARS-CoV-2 infection.
  • the viral infection is a SARS-CoV-2 infection.
  • a second aspect is a method of treating a coronavirus infection in a subject in need thereof, comprising administering an effective amount of a Syk inhibitor, or a pharmaceutically acceptable salt thereof, to the subject.
  • said treatment is an anti-viral treatment.
  • the administration of the Syk inhibitor reduces the viral load in the subject.
  • the Syk inhibitor is administered prior to COVID-19 pneumonia development.
  • the Syk inhibitor is administered prior to the subject developing a severe cytokine storm.
  • the subject has a mild to moderate SARS-CoV-2 infection.
  • the subject is asymptomatic at the start of the administration regimen.
  • a third aspect relates to the use of a Syk inhibitor for the manufacture of a medicament for the treatment of viral infections.
  • said treatment is an antiviral treatment.
  • SARS-CoV-2 directly enters cells expressing ACE2 via receptor-mediated endocytosis (Hoffmann, et al.). Successful viral replication requires host endosome acidification to release the viral genome into the host cytosol. Innate immune cells like monocytes, macrophages and neutrophils do not highly express ACE2, but have abundant Fc receptors (Zou, et al.; Qi, et al.; Lu, et al., Nat. Rev. Imm. 2018 https://doi.org/10.1038/nri.2017.106).
  • Fc receptors Fc receptors
  • CR complement receptors
  • ssRNA virus can induce NETosis in neutrophils (Saitoh, et al., Cell Host Microbe (2012), 19; 12(1): 109-16) leading to release of DNA and RNA, creating a feed-forward loop to further fuel inflammation (Herster et al., Nat Commun 2020; 11, 105 https://doi.org/10.1038/s41467- 019-13756-4), which has been proposed as a driver of severe COVID-19 (Barnes, et al., J Exp med 2020; 217 (6) https://doi.org/10.1084/jem.20200652).
  • SARS-CoV-1 derived ssRNA has been shown to mediate severe lung pathology in animal models and presents as a potential driver of virus-associated cytokine storm (Li, et al., Microbes Infect 2013; 15 (2) 88-95. https://doi.Org/10.1016/j.micinf.2012.10.008).
  • SARS-CoV-2 Some patients infected with SARS-CoV-2 develop in the course of disease progression severe lung pathology as well as other organ dysfunction including myocardial injury, acute kidney injury, shock resulting in endothelial dysfunction and subsequently micro and macrovascular thrombosis. These organ dysfunctions are assumed to be caused by a hyperinflammatory immune response. Accordingly, Syk inhibitors have been suggested as possible treatment to control the hyperinflammatory response at the later stages of SARS-CoV- 2 disease progression.
  • Syk inhibitors may, independent of its effect on the immune system, have the capacity to affect the life cycle of SARS-CoV-2, reduce the viral load in cells infected with SARS-CoV-2 and/or reduce the number of cells infected with SARS-CoV-2 virus.
  • Syk inhibitors may provide for effects at the early stages of infection that may allow a subject infected with SARS-CoV-2 to avoid severe disease.
  • Syk inhibitor refers to a compound that has a biological effect to inhibit, significantly reduce or down-regulate the biological activity of Syk (spleen tyrosine kinase). In some embodiments, the Syk inhibitor specifically binds to Syk and inhibits the kinase activity of Syk. In some embodiments, the term “Syk inhibitor” refers specifically to the compounds defined in items [9], [10] or [11] below. In some embodiments, the term “Syk inhibitor” refers specifically to the compounds defined in Table 1 below.
  • COVID-19 is the name of the disease which is caused by a SARS-CoV-2 infection. While care was taken to describe both the infection and disease with accurate terminology, “COVID-19” and “SARS-CoV-2 infection” are meant to be equivalent terms.
  • “mild to moderate” COVID-19 occurs when the subject presents as asymptomatic or with less severe clinical symptoms (e.g., low grade or no fever ( ⁇ 39.1 °C), cough, mild to moderate discomfort) with no evidence of pneumonia, and generally does not require medical attention.
  • “moderate to severe” infection generally patients present with more severe clinical symptoms (e.g., fever >39.1 °C, shortness of breath, persistent cough, pneumonia, etc.).
  • “moderate to severe” infection typically requires medical intervention, including hospitalization. During the progression of disease, a subject can transition from “mild to moderate” to “moderate to severe” and back again in one course of bout of infection.
  • Treatment of COVID-19 using the methods of this invention include administration of an effective amount of a Syk inhibitor of the invention at any stage of the infection, preferably an early stage of the infection, to prevent or reduce the symptoms associated therewith.
  • subjects will be administered an effective amount of a Syk inhibitor of the invention after definitive diagnosis and presentation with symptoms consistent with a SARS-CoV2 infection, and administration will reduce the severity of the infection and/or prevent progression of the infection to a more severe state.
  • the clinical benefits upon such administration is described in more detail in the sections below.
  • the Syk inhibitor is a compound according to Formula (A)
  • A is at each occurrence independently selected from the group consisting of N and CH;
  • T is selected from the group consisting of H, NH2 and CH3, wherein 1 to
  • I is selected from the group consisting of P 1 , P 2 and P 3 ;
  • P 1 is a Cs-Cs-cycloalkyl which is unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, CN, OH, NH2, NHR 3a , N(R 3a )2, OR 3a and/or R 3a ;
  • P 2 is selected from the group consisting of phenyl and an aromatic monocyclic 5-, 6- or 7-membered heterocycle, wherein the heterocyclic system of said aromatic monocyclic 5-, 6- or 7-membered heterocycle contains 1, 2 or 3 N, O and/or S atoms, wherein said phenyl or aromatic monocyclic 5-, 6- or 7-membered heterocycle is unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, Het, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • P 3 is a bicyclic 9- or 10-membered heterocycle, wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms, wherein at least one ring of said bicyclic 9- or 10-membered heterocycle is aromatic, and wherein said bicyclic 9- or 10-membered heterocycle is unsubstituted or mono-, di-, tri-, or tetrasubstituted by Hal, CN, OH, NH2, NHR 3a , N(R 3a ) 2 , OR 3a , and/or R 3a ;
  • Vi is selected from the group consisting of NH and O;
  • V2 is selected from the group consisting of NH2, OH, NHR 3a , N(R 3a )2 and
  • R 3a , R 3b are, independently from one another, selected from the group consisting of the group consisting of a linear or branched Ci-Ce-alkyl or C3-C8 cycloalkyl, wherein 1 to 5 H atoms may be replaced by Hal, CN, OH and/or OAlk;
  • Het is a 5-membered aromatic heterocycle wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms.
  • Such compounds can be prepared by standard methods of synthetic organic chemistry (see e.g. March's Advanced Organic Chemistry, 8th ed. (2020), John Wiley & Sons, Inc., Hoboken, NJ, U.S.A.). The general synthetic accessibility of such compounds is described in WO 2014/023385 Al. Similar compounds can be prepared by using appropriate building blocks.
  • the Syk inhibitor is a compound according to Formula (A)
  • A is N;
  • T is selected from the group consisting of H, NH2 and CHF2;
  • I is selected from the group consisting of P 1 , P 2 and P 3 ;
  • P 1 is cyclohexyl which is unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, CN, OH, NH2, NHR 3a , N(R 3a )2, OR 3a and/or R 3a ;
  • P 2 is selected from the group consisting of phenyl and 4-pyrazolyl, wherein said phenyl or 4-pyrazolyl is unsubstituted or mono-, di-, trior tetrasubstituted by Hal, Het, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ; which is unsubstituted or mono-, di-, tri-, or tetrasubstituted by Hal, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • Vi is NH
  • V 2 is selected from the group consisting of NH 2 and OH;
  • R 3a , R 3b are, independently from one another, selected from the group consisting of the group consisting of a linear or branched Ci-Ce-alkyl or Cs-Cs cycloalkyl, wherein 1 to 5 H atoms may be replaced by Hal, CN, OH and/or OAlk;
  • Het is a 5-membered aromatic heterocycle wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms.
  • Such compounds can be prepared by standard methods of synthetic organic chemistry (see e.g. March's Advanced Organic Chemistry, 8th ed. (2020), John Wiley & Sons, Inc., Hoboken, NJ, U.S.A.). The general synthetic accessibility of such compounds is described in WO 2014/023385 Al. Similar compounds can be prepared by using appropriate building blocks.
  • the Syk inhibitor is a compound according to Formula (A)
  • A is N;
  • T is selected from the group consisting of H, NH2 and CHF2;
  • I is selected from the group consisting of P 1 , P 2 and P 3 ;
  • P 1 is cyclohexyl which is unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, CN, OH, NH2, NHR 3a , N(R 3a )2, OR 3a and/or R 3a ;
  • P 2 is selected from the group consisting of phenyl and 4-pyrazolyl, wherein said phenyl or 4-pyrazolyl is unsubstituted or mono-, di-, trior tetrasubstituted by Hal, Het, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • P 3 is which is unsubstituted or mono-, di-, tri-, or tetrasubstituted by Hal, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • Vi is NH
  • V2 is selected from the group consisting of NH2 and OH;
  • R 3a , R 3b are, independently from one another, selected from the group consisting of the group consisting of a linear or branched Ci-Ce-alkyl or C3-C8 cycloalkyl, wherein 1 to 5 H atoms may be replaced by Hal, CN, OH and/or OAlk;
  • Het is a 5-membered aromatic heterocycle wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms.
  • Such compounds can be prepared by standard methods of synthetic organic chemistry (see e.g. March's Advanced Organic Chemistry, 8th ed. (2020), John Wiley & Sons, Inc., Hoboken, NJ, U.S.A.). The general synthetic accessibility of such compounds is described in WO 2014/023385 Al. Similar compounds can be prepared by using appropriate building blocks.
  • the Syk inhibitor is a compound selected from Table 1 below:
  • the Syk inhibitor is a compound according to Formula (1):
  • Compound 1 The compound according to Formula (1) is referred to herein also as "Compound 1".
  • This compound is a pyridopyrimidine derivative and may also be referred to as 3-[2-((lR,2S)-2- Amino-cyclohexylamino)-5-difluoromethyl-pyrido[4,3-d]pyrimidin-8-yl]-lH-indole-6- carbonitrile. It is disclosed and further characterized in published international patent application WO 2014/023385 Al (see Example 87).
  • One embodiment of the present disclosure is the use of a compound according to Formula (A) as defined above or a pharmaceutically acceptable salt and/or solvate or hydrate thereof for the treatment of a viral infection.
  • One embodiment of the present disclosure is the use of a compound according to Formula (1) to (31) or a pharmaceutically acceptable salt and/or solvate or hydrate thereof for the treatment of a viral infection.
  • One embodiment of the present disclosure is the use of a compound according to Formula (1) or a pharmaceutically acceptable salt and/or solvate or hydrate thereof for the treatment of a viral infection.
  • the Syk inhibitor used in the treatment of the present disclosure can e.g. be a Compound according to Formula (A) as defined above, in particular a Compound according to Formula (1) to (31) as defined above.
  • Syk inhibitors such as a Compound according to Formula (A) as defined above, in particular one of the Compounds 1 to 31, may either be used in their free form or as pharmaceutically acceptable salts.
  • Such pharmaceutically acceptable salts can be derived from various organic and inorganic acids and bases by procedures known in the art.
  • Pharmaceutically acceptable salt forms of Syk inhibitors, and in particular of a Compound according to Formula (A) as defined above, in particular of one of the compounds of Formula (1) to (31), are for the most part prepared by conventional methods.
  • a Syk inhibitor used in the present invention contains a carboxyl group
  • one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt.
  • bases are, for example, alkali metal hydroxides, including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, diethanolamine and N methylglutamine.
  • the aluminium salts of Syk inhibitors according to the present disclosure are likewise included.
  • acidaddition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl-sulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and corresponding salts thereof, such as acetate, trifluoro-acetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like.
  • organic and inorganic acids for example hydrogen halides, such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoaryl-
  • pharmaceutically acceptable acid-addition salts of the compound of Formula (1) include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentane propionate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecyl sulfate, ethane-sulfonate, formate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, hemi succinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydro-bromide, hydroiodide,
  • the base salts of the Syk inhibitors that may be used in the present disclosure include aluminium, ammonium, calcium, copper, iron(III), iron(II), lithium, magnesium, manganese(III), manganese(II), potassium, sodium and zinc salts, but this is not intended to represent a restriction.
  • Salts of Syk inhibitors which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic ion exchanger resins, for example arginine, betaine, caffeine, chloroprocaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclohexylamine, diethanol-amine, diethylamine, 2 diethylaminoethanol, 2 dimethylaminoethanol, ethanolamine, ethylenediamine, N ethylmorpholine, N ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lido-caine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resins, procaine,
  • Syk inhibitors which contain basic nitrogen-containing groups can be quaternized using agents such as (Cl-C4)alkyl halides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(Cl-C4)alkyl sulfates, for example dimethyl, diethyl and diamyl sulfate; (C10-C18)alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl-(Cl-C4)alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-soluble compounds according to the invention can be prepared using such salts.
  • (Cl-C4)alkyl halides for example methyl, ethyl, isopropyl and tert-but
  • the above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemi succinate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine, but this is not intended to represent a restriction.
  • hydrochloride di hydrochloride, hydro-bromide, maleate, mesylate, phosphate, sulfate and succinate.
  • the acid-addition salts of basic Syk inhibitors are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner.
  • the free base can be regenerated by bringing the salt form into contact with a base and isolating the free base in a conventional manner.
  • the free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free base forms thereof.
  • the pharmaceutically acceptable base-addition salts of the Syk inhibitors formed with metals or amines such as alkali metals and alkaline earth metals or organic amines.
  • metals are sodium, potassium, magnesium and calcium.
  • Preferred organic amines are N,N’ -dibenzylethylenediamine, chloroprocaine, choline, diethanol-amine, ethylenediamine, N-methyl-D-glucamine and procaine.
  • the base-addition salts of acidic compounds according to the invention are prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conventional manner.
  • the free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional manner.
  • the free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof.
  • a Syk inhibitor according to the present disclosure contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts.
  • Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di-phosphate, disodium and trihydrochloride, but this is not intended to represent a restriction.
  • the expression "pharmaceutically acceptable salt” in the present connection is taken to mean an active ingredient which comprises a Syk inhibitor, such as a Compound according to Formula (A) as defined above, the compound according to Formula (1) or any other of Compounds 1 to 31, in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier.
  • a Syk inhibitor such as a Compound according to Formula (A) as defined above
  • the compound according to Formula (1) or any other of Compounds 1 to 31 in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier.
  • the pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • the group comprises one or more deuterium atoms.
  • said Syk inhibitor is a Syk inhibitor as defined, but not a pharmaceutically acceptable salt or solvate or hydrate thereof.
  • the term “patient” or “subject”, as used herein, means an animal, preferably a human. However, “subject” can include companion animals such as dogs and cats.
  • the subject is an adult human patient.
  • the subject is a pediatric patient.
  • Pediatric patients include any human which is under the age of 18 at the start of treatment.
  • Adult patients include any human which is age 18 and above at the start of treatment.
  • the subject is a member of a high-risk group, such as being over 65 years of age, immunocompromised humans of any age, humans with chronic lung conditions (such as, asthma, COPD, cystic fibrosis, etc.), and humans with other comorbidities.
  • the other co-morbidity is obesity, diabetes, and/or hypertension.
  • compositions can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods.
  • oral including buccal or sublingual
  • rectal including buccal or sublingual
  • nasal including buccal, sublingual or transdermal
  • vaginal or parenteral including subcutaneous, intramuscular, intravenous or intradermal
  • parenteral including subcutaneous, intramuscular, intravenous or intradermal
  • compositions adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
  • the active-ingredient component in the case of oral administration in the form of a tablet or capsule, can be combined with an oral, non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like.
  • an oral, non-toxic and pharmaceutically acceptable inert excipient such as, for example, ethanol, glycerol, water and the like.
  • Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for example, an edible carbohydrate, such as, for example, starch or mannitol.
  • a flavour, preservative, dispersant and dye may likewise be present.
  • Capsules are produced by preparing a powder mixture as described above and filling shaped gelatine shells therewith.
  • Glidants and lubricants such as, for example, highly disperse silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation.
  • a disintegrant or solubiliser such as, for example, agar-agar, calcium carbonate or sodium carbonate, may likewise be added in order to improve the availability of the medicament after the capsule has been taken.
  • suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
  • the lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
  • the disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like.
  • the tablets are formulated by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant and pressing the entire mixture to give tablets.
  • a powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl-pyrrolidone, a dissolution retardant, such as, for example, paraffin, an ab-sorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate.
  • a binder such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl-pyrrolidone
  • a dissolution retardant such as, for example, paraffin
  • an ab-sorption accelerator such as, for example, a quaternary salt
  • an absorbant such as, for example, bentonite, kaolin or dicalcium phosphate.
  • the powder mixture can be granulated by wetting it with a binder, such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve.
  • a binder such as, for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials
  • the powder mixture can be run through a tabletting machine, giving lumps of non-uniform shape, which are broken up to form granules.
  • the granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets.
  • the compounds according to the disclosure can also be combined with a free- flowing inert excipient and then pressed directly to give tablets without carrying out the granulation or dry-pressing steps.
  • a transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units.
  • Oral liquids such as, for example, solution, syrups and elixirs, can be pre-pared in the form of dosage units so that a given quantity comprises a pre-specified amount of the compound.
  • Syrups can be prepared by dissolving the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle.
  • Suspensions can be formulated by dispersion of the compound in a non-toxic vehicle.
  • Solubilisers and emulsifiers such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners and the like, can likewise be added.
  • the dosage unit formulations for oral administration can, if desired, be encapsulated in microcapsules.
  • the formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, by coating or embedding of particulate material in polymers, wax and the like.
  • the compounds according to Formula (A) above, in particular compounds of the formula (1) to (31), and salts, solvates and physiologically functional derivatives thereof can also be administered in the form of lipo-some delivery systems, such as, for example, small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
  • liposomes can be formed from various phospholipids, such as, for example, cholesterol, stearylamine or phosphatidylcholines.
  • the compounds according to Formula (A) above, in particular compounds of the formula (1) to (31), and the salts, solvates, enantiomers, tautomer and stereoisomers thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled.
  • the compounds can also be coupled to soluble polymers as targeted medicament carriers.
  • Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamido-phenol, polyhydroxyethylaspartamidophenol or polyethylene oxide poly-lysine, substituted by palmitoyl radicals.
  • the compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, poly-hydroxybutyric acid, poly-orthoesters, poly-acetals, poly-dihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, poly-hydroxybutyric acid, poly-orthoesters, poly-acetals, poly-dihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
  • compositions adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient.
  • the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986).
  • Pharmaceutical compounds adapted for topical administration can be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
  • the formulations are preferably applied as topical ointment or cream.
  • the active ingredient can be employed either with a paraffinic or a water- miscible cream base.
  • the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base.
  • compositions adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, in particular an aqueous solvent.
  • compositions adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes.
  • compositions adapted for rectal administration can be administered in the form of suppositories or enemas.
  • compositions adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal pas-sages from a container containing the powder held close to the nose.
  • Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil.
  • compositions adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insufflators.
  • Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations.
  • compositions adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxidants, buffers, bacteriostatics and solutes, by means of which the formulation is rendered isotonic with the blood of the recipient to be treated; and aqueous and non-aqueous sterile suspensions, which may comprise sus-pension media and thickeners.
  • the formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried (lyophilised) state, so that only the addition of the sterile carrier liquid, for example water for injection purposes, immediately before use is necessary.
  • Injection solutions and suspensions pre-pared in accordance with the recipe can be prepared from sterile powders, granules and tablets.
  • formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, formulations which are suitable for oral administration may comprise flavours.
  • a therapeutically effective amount of a Syk inhibitor such as a compound according to Formula (A) above, in particular a compound of Formula (1) to (31), depends on a number of factors, including, for example, the age and weight of the subject, the precise condition that requires treatment, and its severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet.
  • an effective amount of a compound according to the invention is generally in the range from 0.1 to 100 mg/kg of body weight of the recipient (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day.
  • the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same.
  • An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be determined as the fraction of the effective amount of the compound according to the invention per se. It can be assumed that similar doses are suitable for the treatment of other conditions mentioned above.
  • Compositions of the present invention are administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • the compositions are administered orally.
  • the oral formulation of a compound of the invention is a tablet or capsule form.
  • the oral formulation is a solution or suspension which may be given to a subject in need thereof via mouth or nasogastric tube. Any oral formulations of the invention may be administered with or without food.
  • pharmaceutically acceptable compositions of this invention are administered without food.
  • pharmaceutically acceptable compositions of this invention are administered with food.
  • compositions of this invention are orally administered in any orally acceptable dosage form.
  • exemplary oral dosage forms are capsules, tablets, aqueous suspensions or solutions.
  • carriers commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents are optionally also added.
  • compositions of the present invention that are optionally combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, and the particular mode of administration.
  • provided compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the compound can be administered to a patient receiving these compositions.
  • the Syk inhibitor can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit.
  • a unit can comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a Syk inhibitor according to the present disclosure, depending on the method of administration and the age, weight and condition of the patient, or a Syk inhibitor according to the present disclosure can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit.
  • Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient.
  • pharmaceutical formulations of this type can be prepared using a process which is generally known in the pharmaceutical art.
  • the total amount of Syk inhibitor administered to the subject in need thereof is between about 5 mg to about 1000 mg per day.
  • the Syk inhibitor is administered once a day. In another aspect of this embodiment, the Syk inhibitor is administered twice a day.
  • the Syk inhibitor is administered for a period of about 7 days to about 28 days (preferably, " about 7 days to about 28 days” means for at least 7 ⁇ 0.5 days, but not more than 21 days ⁇ 0.5 days). In one aspect of any of the above embodiments, the Syk inhibitor is administered for about 14 days (preferably, "about 14 days” means for 14 days ⁇ 0.5 days).
  • the subject is suffering from COVID-19 pneumonia.
  • the subject is suffering from one or more symptoms selected from chest congestion, cough, blood oxygen saturation (SpO2) levels below 94%, shortness of breath, difficulty breathing, fever, chills, repeated shaking with chills, muscle pain and/or weakness, headache, sore throat and/or new loss of taste or smell.
  • SpO2 blood oxygen saturation
  • the subject is suffering from a hyperinflammatory host immune response to a SARS-CoV-2 infection. In one embodiment, the subject is not suffering from a hyperinflammatory host immune response to a SARS-CoV-2 infection.
  • the hyperinflammatory host immune response is associated with one or more clinical indications selected from 1) reduced levels of lymphocytes, especially natural killer (NK) cells in peripheral blood; 2) high levels of inflammatory parameters (e.g., C reactive protein [CRP], ferritin, d-dimer), and pro-inflammatory cytokines (e.g., IL-6, TNF-alpha, IL- 8, and/or IL-lbeta; 3) a deteriorating immune system demonstrated by lymphocytopenia and/or atrophy of the spleen and lymph nodes, along with reduced lymphocytes in lymphoid organs; 4) dysfunction of the lung physiology represented by lung lesions infiltrated with monocytes, macrophages, and/or neutrophils, but minimal
  • the subject with COVID-19 is a pediatric patient suffering from vasculitis, including Kawasaki disease (i.e., Kawasaki syndrome) and Kawasaki-like disease.
  • Kawasaki disease i.e., Kawasaki syndrome
  • Kawasaki-like disease i.e., Kawasaki-like disease.
  • the subject is being treated inpatient in a hospital setting. In another embodiment, the subject is being treated in an outpatient setting. In one aspect of the preceding embodiments, the subject may continue administration of the Syk inhibitor after being transitioned from being treated from an inpatient hospital setting to an outpatient setting.
  • the administration of the Syk inhibitor results in one or more clinical benefit.
  • the one or more clinical benefit is selected from the group consisting of: reduction of duration of a hospital stay, reduction of the duration of time in the Intensive Care Unit (ICU), reduction in the likelihood of the subject being admitted to an ICU, reduction in the rate of mortality, reduction in the likelihood of kidney failure requiring dialysis, reduction in the likelihood of being put on non-invasive or invasive mechanical ventilation, reduction of the time to recovery, reduction in the likelihood that supplemental oxygen will be needed, improvement or normalization in the peripheral capillary oxygen saturation (SpCh levels) without mechanical intervention, reduction of severity of the pneumonia as determined by chest imaging (e.g., CT or chest X ray), reduction in the cytokine production, reduction of the severity of acute respiratory distress syndrome (ARDS), reduction in the likelihood of developing ARDS, clinical resolution of the COVID-19 pneumonia, improvement of the PaO2/FiO2 ratio, and reduction of the inflammatory response in the subject.
  • chest imaging e.g., CT or chest X
  • the one or more clinical benefits include the improvement or normalization in the peripheral capillary oxygen saturation (SpO2 levels) in the subject without mechanical ventilation or extracorporeal membrane oxygenation.
  • SpO2 levels peripheral capillary oxygen saturation
  • the one or more clinical benefits include the reduction of the inflammatory response of the subject.
  • the reduction of the inflammatory response in the subject results in the reduction of proinflammatory cytokine release driven by NF-kappa-B, IL-lb, IL-6, IL-8, IL-12, IL-18, IL-23, or IL-27, alone or in combination with inhibition of cytokine release driven by IRF3/7, such as type I IFNs, including IFN-alpha and/or IFN-beta.
  • the one or more clinical benefits includes the avoidance of a severe cytokine storm in the subject.
  • the one of more clinical benefits is reduction in the likelihood of being hospitalized, reduction in the likelihood of ICU admission, reduction in the likelihood of being intubated (invasive mechanical ventilation), reduction in the likelihood that supplemental oxygen will be needed, reduction in the length of hospital stay, reduction in the likelihood of mortality, and/or a reduction in likelihood of relapse, including the likelihood of rehospitalization.
  • the invention also provides a method of treating a viral infection in a subject in need thereof comprising administering an effective amount of a compound of the invention to the subject.
  • An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control subjects.
  • said treatment is an anti-viral treatment.
  • One aspect of the invention is a method of treating a coronavirus infection in a subject in need thereof, comprising administering an effective amount of a Syk inhibitor, or a pharmaceutically acceptable salt thereof, to the subject.
  • said treatment is an anti-viral treatment.
  • the subject is infected with SARS-CoV-2.
  • the administration of the Syk inhibitor results in the reduction of the viral load in the subject.
  • the administration of the Syk inhibitor results in the reduction of virus-infected cells in the subject.
  • the administration of the Syk inhibitor results in the reduction of virus-infected cells in the subject during the first 10 days after infection.
  • the administration of the Syk inhibitor results in the reduction of virus-infected cells in the subject during the first 7 days after infection. In another embodiment, the administration of the Syk inhibitor results in the reduction of virus- infected cells in the subject during the time span of day 5 to 10 after infection. In another embodiment, the administration of the Syk inhibitor results in the reduction of virus-infected cells in the subject during the time span of day 3 to 7 after infection. In another embodiment, the administration of the Syk inhibitor results in the reduction of virus-infected cells in the subject during the time span of day 5 to 7 after infection.
  • the Syk inhibitor is administered prior to COVID-19 pneumonia development. In one embodiment, the Syk inhibitor is administered prior to the subject developing a cytokine storm. In another embodiment, the subject has a mild to moderate SARS-CoV-2 infection. In a further embodiment, the subject is asymptomatic at the start of the administration regimen. In another embodiment, the subject has had known contact with a patient who has been diagnosed with a SARS-CoV-2 infection. In an additional embodiment, the subject begins administration of the Syk inhibitor prior to being formally diagnosed with COVID-19. In one embodiment, said Syk inhibitor is administered during the first 10 days after infection with SARS-CoV-2. In one embodiment, said Syk inhibitor is administered during the first 7 days after infection with SARS-CoV-2.
  • said Syk inhibitor is administered during the time span of day 5 to 10 after infection. In another aspect of this embodiment, said Syk inhibitor is administered during the time span of day 3 to 7 after infection. In another aspect of this embodiment, said Syk inhibitor is administered during the time span of day 5 to 7 after infection.
  • One embodiment is a method of treating a subject with COVID-19 comprising administration of an effective amount of a Syk inhibitor to the subject.
  • the subject has been previously vaccinated with a SARS-CoV-2 vaccine and develops vaccine-related exacerbation of infection, for example, an antibody-dependent enhancement or related antibody-mediated mechanisms of vaccine/antibody-related exacerbation.
  • the administration of the Syk inhibitor results in one or more clinical benefits to the subject.
  • the one or more clinical benefits is shortening the duration of infection, reduction of the likelihood of hospitalization, reduction in the likelihood of mortality, reduction in the likelihood of ICU admission, reduction in the likelihood of being placed on mechanical ventilation, reduction in the likelihood that supplemental oxygen will be needed, and/or reduction in the length of hospital stay.
  • the one or more clinical benefits is avoidance of a significant proinflammatory response.
  • the one or more clinical benefit is the failure of the subject to develop significant symptoms of COVID-19.
  • the compounds of the invention can be administered before or following an onset of SARS-CoV-2 infection, or after acute infection has been diagnosed in a subject.
  • the aforementioned compounds and medical products of the inventive use are particularly used for the therapeutic treatment.
  • a therapeutically relevant effect relieves to some extent one or more symptoms of a disorder, or returns to normality, either partially or completely, one or more physiological or biochemical parameters associated with or causative of a disease or pathological condition.
  • Monitoring is considered as a kind of treatment provided that the compounds are administered in distinct intervals, e.g. in order to boost the response and eradicate the pathogens and/or symptoms of the disease.
  • the methods of the invention can also be used to reduce the likelihood of developing a disorder or even prevent the initiation of disorders associated with COVID-19 in advance of the manifestation of mild to moderate disease, or to treat the arising and continuing symptoms of an acute infection.
  • Treatment of mild to moderate CO VID-19 is typically done in an outpatient setting.
  • Treatment of moderate to severe COVID-19 is typically done inpatient in a hospital setting. Additionally, treatment can continue in an outpatient setting after a subject has been discharged from the hospital.
  • the invention furthermore relates to a medicament comprising at least one compound according to the invention or a pharmaceutically acceptable salt thereof.
  • a “medicament” in the meaning of the invention is any agent in the field of medicine, which comprises one or more compounds of the invention or preparations thereof (e.g. a pharmaceutical composition or pharmaceutical formulation) and can be used in prophylaxis, therapy, follow-up or aftercare of patients who suffer from clinical symptoms and/or known exposure to COVID-19.
  • the active ingredient may be administered alone or in combination with one or more additional therapeutic agents.
  • a synergistic or augmented effect may be achieved by using more than one compound in the pharmaceutical composition.
  • the active ingredients can be used either simultaneously or sequentially.
  • the Syk inhibitor is administered in combination with one or more additional therapeutic agents.
  • the one or more additional therapeutic agents is selected from anti-inflammatories, antibiotics, anti-coagulants, antiparasitic agent, antiplatelet agents and dual antiplatelet therapy, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta-blockers, statins and other combination cholesterol lowering agents, specific cytokine inhibitors, complement inhibitors, anti-VEGF treatments, JAK inhibitors, immunomodulators, anti-inflammasome therapies, sphingosine-1 phosphate receptors binders, N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonists, corticosteroids, Granulocyte-macrophage colony-stimulating factor (GM-CSF), anti-GM-CSF, interferons, angiotensin receptor-neprilysin inhibitors, calcium channel blockers, vasodilators,
  • ACE angiotensin converting enzyme
  • the Syk inhibitor is administered in combination with an antiviral agent.
  • the antiviral agent is remdesivir.
  • the antiviral agent is lopinavir-ritonavir, alone or in combination with ribavirin and interferon-beta.
  • the Syk inhibitor is administered in combination with a broadspectrum antibiotic.
  • the Syk inhibitor is administered in combination with chloroquine or hydroxychloroquine. In one aspect of this embodiment, the Syk inhibitor is further combined with azithromycin.
  • the Syk inhibitor is administered in combination with interferon- 1 -beta (Rebif®).
  • the Syk inhibitor is administered in combination with one or more additional therapeutic agents selected from hydroxychloroquine, chloroquine, ivermectin, tranexamic acid, nafamostat, virazole, ribavirin, lopinavir/ritonavir, favipiravir, arbidol, leronlimab, interferon beta-la, interferon beta-lb, beta-interferon, azithromycin, nitrazoxamide, lovastatin, clazakizumab, adalimumab, etanercept, golimumab, infliximab, sarilumab, tocilizumab, anakinra, emapalumab, pirfenidone, belimumab, rituximab, ocrelizumab, anifrolumab, ravulizumab-cwvz,
  • the Syk inhibitor is administered in combination with one or more anti-inflammatory agent.
  • the anti-inflammatory agent is selected from corticosteroids, steroids, COX-2 inhibitors, and non-steroidal antiinflammatory drugs (NSAID).
  • the anti-inflammatory agent is diclofenac, etodolac, fenoprofen, flurbirprofen, ibuprofen, indomethacin, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, sulindac, tolmetin, celecoxib, prednisone, hydrocortisone, fludocortisone, betham ethasone, prednisolone, triamcinolone, methylprednisone, dexamethasone, fluticasone, and budesonide (alone or in combination with formoterol, salmeterol, or vilanterol).
  • the Syk inhibitor is administered in combination with one or more immune modulators.
  • the immune modulator is a calcineurin inhibitor, antimetabolite, or alkylating agent.
  • the immune modulator is selected from azathioprine, mycophenolate mofetil, methotrexate, dapson, cyclosporine, cyclophosphamide, and the like.
  • the Syk inhibitor is administered in combination with one or more antibiotics.
  • the antibiotic is a broad-spectrum antibiotic.
  • the antibiotic is a pencillin, anti- straphylococcal penicillin, cephalosporin, aminopenicillin (commonly administered with a beta lactamase inhibitor), monobactam, quinoline, aminoglycoside, lincosamide, macrolide, tetracycline, glycopeptide, antimetabolite or nitroimidazole.
  • the antibiotic is selected from penicillin G, oxacillin, amoxicillin, cefazolin, cephalexin, cephotetan, cefoxitin, ceftriazone, augmentin, amoxicillin, ampicillin (plus sulbactam), piperacillin (plus tazobactam), ertapenem, ciprofloxacin, imipenem, meropenem, levofloxacin, moxifloxacin, amikacin, clindamycin, azithromycin, doxycycline, vancomycin, Bactrim, and metronidazole.
  • the Syk inhibitor is administered in combination with one or more anti-coagulants.
  • the anti -coagulant is selected from apixaban, dabigatran, edoxaban, heparin, rivaroxaban, and warfarin.
  • the Syk inhibitor is administered in combination with one or more antiplatelet agents and/or dual antiplatelet therapy.
  • the antiplatelet agent and/or dual antiplatelet therapy is selected from aspirin, clopidogrel, dipyridamole, prasugrel, and ticagrelor.
  • the Syk inhibitor is administered in combination with one or more ACE inhibitors.
  • the ACE inhibitor is selected from benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril and trandolapril.
  • the Syk inhibitor is administered in combination with one or more angiotensin II receptor blockers.
  • the angiotensin II receptor blocker is selected from azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan.
  • the Syk inhibitor is administered in combination with one or more beta-blockers.
  • the beta-blocker is selected from acebutolol, atenolol, betaxolol, bisoprolol/hydrochlorothiazide, bisoprolol, metoprolol, nadolol, propranolol, and sotalol.
  • the Syk inhibitor is administered in combination with one or more alpha and beta-blocker.
  • the alpha and beta-blocker is carvedilol or labetalol hydrochloride.
  • the Syk inhibitor is administered in combination with one or more interferons.
  • the Syk inhibitor is administered in combination with one or more angiotensin receptor-neprilysin inhibitors.
  • the angiotensin receptor-neprilysin inhibitor is sacubitril/valsartan.
  • the Syk inhibitor is administered in combination with one or more calcium channel blockers.
  • the calcium channel blocker is selected from amlodipine, diltiazem, felodipine, nifedipine, nimodipine, nisoldipine, and verapamil.
  • the Syk inhibitor is administered in combination with one or more vasodilators.
  • the one or more vasodilator is selected from isosorbide dinitrate, isosorbide mononitrate, nitroglycerin, and minoxidil.
  • the Syk inhibitor is administered in combination with one or more diuretics.
  • the one or more diuretics is selected from acetazolamide, amiloride, bumetanide, chlorothiazide, chlorthalidone, furosemide, hydrochlorothiazide, indapamide, metalazone, spironolactone, and torsemide.
  • the Syk inhibitor is administered in combination with one or more muscle relaxants.
  • the muscle relaxant is an antispasmodic or antispastic.
  • the one or more muscle relaxants is selected from casisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine, tizanidine, baclofen, dantrolene, and diazepam.
  • the Syk inhibitor is administered in combination with one or more antiviral medications.
  • the antiviral medication is remdesivir.
  • the Syk inhibitor is administered in combination with one or more additional therapeutic agents selected from antiparasitic drugs (including, but not limited to, hydroxychloroquine, chloroquine, ivermectin), antivirals (including, but not limited to, tranexamic acid, nafamostat, virazole [ribavirin], lopinavir/ritonavir, favipiravir, leronlimab, interferon beta-la, interferon beta-lb, beta-interferon), antibiotics with intracellular activities (including, but not limited to azithromycin, nitrazoxamide), statins and other combination cholesterol lowering and anti-inflammatory drugs (including, but not limited to, lovastatin), specific cytokine inhibitors (including, but not limited to, clazakizumab, adalimumab, etanercept, golimumab, infliximab, sarilumab,
  • the combination of a Syk inhibitor with one or more additional therapeutic agents reduces the effective amount (including, but not limited to, dosage volume, dosage concentration, and/or total drug dose administered) of the Syk inhibitor and/or the one or more additional therapeutic agents administered to achieve the same result as compared to the effective amount administered when the Syk inhibitor or the additional therapeutic agent is administered alone.
  • the combination of a Syk inhibitor with the additional therapeutic agent reduces the total duration of treatment compared to administration of the additional therapeutic agent alone.
  • the combination of a Syk inhibitor with the additional therapeutic agent reduces the side effects associated with administration of the additional therapeutic agent alone.
  • the combination of an effective amount of the Syk inhibitor with the additional therapeutic agent is more efficacious compared to an effective amount of the Syk inhibitor or the additional therapeutic agent alone. In one embodiment, the combination of an effective amount of the Syk inhibitor with the one or more additional therapeutic agent results in one or more additional clinical benefits than administration of either agent alone.
  • treatment refers to reversing, alleviating, delaying the onset of, or inhibiting the progress of a viral infection, or one or more symptoms thereof, as described herein.
  • treatment is administered after one or more symptoms have developed.
  • treatment is administered in the absence of symptoms.
  • treatment is administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a known exposure to an infected person and/or in light of comorbidities which are predictors for severe disease, or other susceptibility factors).
  • a method of treating a coronavirus infection in a subject in need thereof comprising administering an effective amount of a Syk inhibitor, or a pharmaceutically acceptable salt or solvate or hydrate thereof, to the subject.
  • a Syk inhibitor or a pharmaceutically acceptable salt or solvate or hydrate thereof for use in the treatment of a coronavirus infection is a pharmaceutically acceptable salt or solvate or hydrate thereof for use in the treatment of a coronavirus infection.
  • A is at each occurrence independently selected from the group consisting of N and CH;
  • T is selected from the group consisting of H, NH2 and CH3, wherein 1 to
  • I is selected from the group consisting of P 1 , P 2 and P 3 ;
  • P 1 is a Cs-Cs-cycloalkyl which is unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, CN, OH, NH2, NHR 3a , N(R 3a )2, OR 3a and/or R 3a ;
  • P 2 is selected from the group consisting of phenyl and an aromatic monocyclic 5-, 6- or 7-membered heterocycle, wherein the heterocyclic system of said aromatic monocyclic 5-, 6- or 7-membered heterocycle contains 1, 2 or 3 N, O and/or S atoms, wherein said phenyl or aromatic monocyclic 5-, 6- or 7-membered heterocycle is unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, Het, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • P 3 is a bicyclic 9- or 10-membered heterocycle, wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms, wherein at least one ring of said bicyclic 9- or 10-membered heterocycle is aromatic, and wherein said bicyclic 9- or 10-membered heterocycle is unsubstituted or mono-, di-, tri-, or tetrasubstituted by Hal, CN, OH, NH2, NHR 3a , N(R 3a ) 2 , OR 3a , and/or R 3a ;
  • Vi is selected from the group consisting of NH and O;
  • V2 is selected from the group consisting of NH2, OH, NHR 3a , N(R 3a )2 and
  • R 3a , R 3b are, independently from one another, selected from the group consisting of the group consisting of a linear or branched Ci-Ce-alkyl or C3-C8 cycloalkyl, wherein 1 to 5 H atoms may be replaced by Hal, CN, OH and/or OAlk;
  • Het is a 5-membered aromatic heterocycle wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms.
  • A is N;
  • T is selected from the group consisting of H, NH2 and CHF2;
  • I is selected from the group consisting of P 1 , P 2 and P 3 ;
  • P 1 is cyclohexyl which is unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, CN, OH, NH2, NHR 3a , N(R 3a )2, OR 3a and/or R 3a
  • P 2 is selected from the group consisting of phenyl and 4-pyrazolyl, wherein said phenyl or 4-pyrazolyl is unsubstituted or mono-, di-, trior tetrasubstituted by Hal, Het, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • P 3 is which is unsubstituted or mono-, di-, tri-, or tetrasubstituted by Hal, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • Vi is NH
  • V 2 is selected from the group consisting of NH 2 and OH;
  • R 3a , R 3b are, independently from one another, selected from the group consisting of the group consisting of a linear or branched Ci-Ce-alkyl or Cs-Cs cycloalkyl, wherein 1 to 5 H atoms may be replaced by Hal, CN, OH and/or OAlk;
  • Het is a 5-membered aromatic heterocycle wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms.
  • T is selected from the group consisting of H, NH2 and CHF2;
  • I is selected from the group consisting of P 1 , P 2 and P 3 ;
  • P 1 is cyclohexyl which is unsubstituted or mono-, di-, tri- or tetrasubstituted by Hal, CN, OH, NH2, NHR 3a , N(R 3a )2, OR 3a and/or R 3a ;
  • P 2 is selected from the group consisting of phenyl and 4-pyrazolyl, wherein said phenyl or 4-pyrazolyl is unsubstituted or mono-, di-, trior tetrasubstituted by Hal, Het, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • P 3 is which is unsubstituted or mono-, di-, tri-, or tetrasubstituted by Hal, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • Vi is NH
  • V2 is selected from the group consisting of NH2 and OH;
  • R 3a , R 3b are, independently from one another, selected from the group consisting of the group consisting of a linear or branched Ci-Ce-alkyl or C3-C8 cycloalkyl, wherein 1 to 5 H atoms may be replaced by Hal, CN, OH and/or OAlk;
  • Het is a 5-membered aromatic heterocycle wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms.
  • A is N;
  • T is selected from the group consisting of H, NH2 and CHF2;
  • I is selected from the group consisting of P 2 and P 3 ;
  • P 2 is selected from the group consisting of phenyl and 4-pyrazolyl, wherein said phenyl or 4-pyrazolyl is unsubstituted or mono-, di-, trior tetrasubstituted by Hal, Het, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • P 3 is which is unsubstituted or mono-, di-, tri-, or tetrasubstituted by Hal, CN, OH, NH 2 , NHR 3a , N(R 3a ) 2 , OR 3a and/or R 3a ;
  • Vi is NH
  • V 2 is selected from the group consisting of NH 2 and OH;
  • R 3a , R 3b are, independently from one another, selected from the group consisting of the group consisting of a linear or branched Ci-Ce-alkyl or Cs-Cs cycloalkyl, wherein 1 to 5 H atoms may be replaced by Hal, CN, OH and/or OAlk;
  • Het is a 5-membered aromatic heterocycle wherein the heterocyclic system contains 1, 2 or 3 N, O and/or S atoms.
  • Syk inhibitor (or the pharmaceutically acceptable salt or solvate or hydrate thereof) for use according to any one of [2] or [4] to [25] or the use according to any one of [3] to [25], wherein said use involves administration of said Syk inhibitor to a subject in need thereof.
  • the one or more additional therapeutic agents is selected from anti-inflammatories, antibiotics, anti-coagulants, antiparasitic agent, antiplatelet agents and dual antiplatelet therapy, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, beta-blockers, statins and other combination cholesterol lowering agents, specific cytokine inhibitors, complement inhibitors, anti-VEGF treatments, JAK inhibitors, immunomodulators, anti- inflammasome therapies, sphingosine- 1 phosphate receptors binders, N-methyl-d- aspartate (NDMA) receptor glutamate receptor antagonists, corticosteroids, Granulocytemacrophage colony-stimulating factor (GM-CSF), anti-GM-CSF, interferons, angiotensin receptor-neprilysin inhibitors, calcium channel blockers, va
  • Compound 1 a Syk inhibitor of the pyridopyrimidine class, is prepared in accordance with the procedure disclosed in WO 2014/023385 Al (Example 87), as illustrated by the following reaction scheme:
  • Trifluoroacetic acid 28,28 pl; 0,367 mmol; 0,600 eq.
  • N-Iodosuccinimide for synthesis 96.33 mg; 0.428 mmol; 0.700 eq.
  • the reaction was treated with water and 0.1N sodiumthiosulfate solution and stirred for about 20 minutes while cooling down to room temperature.
  • the precipitate was filtered off and washed with water and DCM. This gives 197 mg (85%) of the title compound as a yellow solid; LC/MS (Method G): (percent area) 93.5 %; Rt 2.291 min.; (M+H) 354.
  • Plates were imaged using the ImageXpress Micro Confocal High-Content Imaging System (Molecular Devices) with a 10x objective, with 4 fields imaged per well. Images were analyzed using the Multi -Wavelength Cell Scoring Application Module (MetaXpress), with DAPI staining identifying the host-cell nuclei (the total number of cells in the images) and the SARS-CoV-2 immunofluorescence signal leading to identification of infected cells.
  • MethodaXpress Multi -Wavelength Cell Scoring Application Module
  • the SARS-CoV-2 EC50 (EC50: half maximal effective concentration) was determined from the "% infected cells” curve, the HeLa-ACE2 CC50 (CC50: 50% cytotoxicity concentration) from the "live cells per well in the uninfected HeLa-ACE2 counter- screen cytotoxicity assay” curve.
  • the Selectivity Index (SI) refers to uninfected HeLa-ACE2 CC50 divided by SARS-CoV-2 EC50.
  • FIG. 1 contains images from the assay for DMSO and remdesivir-treated wells (A), EC50 data for controls from independent experiments (B), and representative dose response curves (C).
  • Figure 2 contains representative dose response curves for Compound 1, i.e. the compound according to Formula (1).
  • Syk inhibitors in particular Compound 1, are effective against SARS-CoV-2.
  • Compound 1 efficiently reduces the fraction of cells that are detected as being infected with SARS-CoV-2. Strong reduction in virus-infected cells is already achieved at a concentration of Compound 1 where uninfected cells are only marginally affected. Since these effects are observed in a cell culture system that only includes the infected cells, but no immune cells, this means that the effects of the Syk inhibitor against the infected cells occur without an involvement of the immune system.
  • Syk inhibitors can be used not only against SARS-CoV-2-induced hyperinflammation at later stages of COVID-19 disease, but also against the viral infection itself at the early stages of the disease.
  • Example 3 Antiviral testing of compounds in Calu3 cells SARS-CoV-2/Calu-3 high-content screening assay
  • Compounds were acoustically transferred into 384-well pel ear-bottom plates (Greiner, Part. No. 781090-2B) and Calu-3 cells were seeded in assay media (MEM with 2% FBS) at a density of 5,000 cells per 20 pL per well.
  • the plated cells were transported to the BSL3 facility where SARS-CoV-2 (strain USA-WA1/2020 propagated in Vero E6 cells) diluted in assay media was added at an MOI between 0.75 and 1 to achieve ⁇ 30 - 60% infected cells. Plates were incubated for 48 h at 34°C 5% CO2, and then fixed with a final concentration of 4% formaldehyde.
  • Plates were imaged using the ImageXpress Micro Confocal High-Content Imaging System (Molecular Devices) with a 10x objective, with 4 fields imaged per well. Images were analyzed using the Multi -Wavelength Cell Scoring Application Module (MetaXpress), with DAPI staining identifying the host-cell nuclei (the total number of cells in the images) and the SARS-CoV-2 immunofluorescence signal leading to identification of infected cells.
  • MethodaXpress Multi -Wavelength Cell Scoring Application Module
  • Curves were fitted as either increasing or decreasing and noted as such in the data output. This is of particular note for the cell count readout from the SARS-CoV-2 infection assay which captures both an antiviral effect, protection from virus-induced cell death (increasing), and cellular toxicity (decreasing).
  • Calu-3 SARS-CoV-2 assay was validated over the course of 12 independent experiments. Cell growth and % infection changed over time resulting in shifts in efficacy for the entry inhibitors and requiring adjustments in MOI. Thus, Calu-3 passage number has been identified as a major determinant for assay performance. Three compound controls were run with each experiment: Remdesivir, Nafamostat, and Puromycin. The half maximal effective concentration (ECso) values fell within 3 -fold of the average for all across 5 independent experiments run using optimal conditions in both antiviral readouts. The assay performed well and RZ’ was routinely >0.4. Performance of controls, infectivity and cell growth were closely monitored and conditions adjusted as needed.

Abstract

La présente invention concerne un inhibiteur de Syk destiné à être utilisé dans le traitement d'infections à coronavirus, notamment la COVID-19, seul ou en combinaison avec un ou plusieurs agents thérapeutiques supplémentaires.
PCT/EP2021/078628 2020-10-16 2021-10-15 Composés pour le traitement d'infections virales WO2022079250A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20202219 2020-10-16
EP20202219.0 2020-10-16

Publications (1)

Publication Number Publication Date
WO2022079250A1 true WO2022079250A1 (fr) 2022-04-21

Family

ID=72964457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2021/078628 WO2022079250A1 (fr) 2020-10-16 2021-10-15 Composés pour le traitement d'infections virales

Country Status (1)

Country Link
WO (1) WO2022079250A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120329785A1 (en) * 2011-04-21 2012-12-27 Origenis Gmbh Novel kinase inhibitors
WO2014023385A1 (fr) 2012-08-07 2014-02-13 Merck Patent Gmbh Dérivés de pyridopyrimidine en tant qu'inhibiteurs de protéine kinase
WO2021183790A1 (fr) * 2020-03-12 2021-09-16 Rigel Pharmaceuticals, Inc. Méthode de traitement d'affections associées au covid-19

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120329785A1 (en) * 2011-04-21 2012-12-27 Origenis Gmbh Novel kinase inhibitors
WO2014023385A1 (fr) 2012-08-07 2014-02-13 Merck Patent Gmbh Dérivés de pyridopyrimidine en tant qu'inhibiteurs de protéine kinase
WO2021183790A1 (fr) * 2020-03-12 2021-09-16 Rigel Pharmaceuticals, Inc. Méthode de traitement d'affections associées au covid-19

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
"March's Advanced Organic Chemistry", 2020, JOHN WILEY & SONS
ANONYMOUS: "Fostamatinib for Hospitalized Adults With COVID-19 - Full Text View - ClinicalTrials.gov", CLINICALTRIALS.ORG, 8 October 2020 (2020-10-08), pages 1 - 9, XP055882029, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04579393> [retrieved on 20220120] *
ANONYMOUS: "Inflammatory Signal Inhibitors for COVID-19 (MATIS) - Full Text View - ClinicalTrials.gov", CLINICALTRAILS.GOV, 9 October 2020 (2020-10-09), pages 1 - 8, XP055882033, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/NCT04581954> [retrieved on 20220120] *
BARNES ET AL., J EXP MED, vol. 217, no. 6, 2020, Retrieved from the Internet <URL:https://doi.org/10.1084/jem.20200652>
FUNG ET AL., ANNU. REV. MICROBIOL., vol. 73, 2019, pages 529 - 57
GEAHLEN, TRENDS PHARMACOL SCI., vol. 35, no. 8, 2014, pages 414 - 422
GREIN ET AL., NEJM, 2020
HE ET AL., NAT MED, 2020, Retrieved from the Internet <URL:https://doi.org/10.1038/s41591-020-0869-5>
HERSTER ET AL., NAT COMMUN, vol. 11, 2020, pages 105, Retrieved from the Internet <URL:https://doi.org/10.1038/s41467-019-13756-4>
HOEPEL WILLIANNE ET AL: "High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages", SCIENCE TRANSLATIONAL MEDICINE, vol. 13, no. 596, 13 July 2020 (2020-07-13), XP055882042, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.abf8654 *
HOFFMANN ET AL., CELL, 2020, Retrieved from the Internet <URL:https://doi.org/10.1016/j.cell.2020.02.052>
LI ET AL., MICROBES INFECT, vol. 15, no. 2, 2013, pages 88 - 95, Retrieved from the Internet <URL:https://doi.org/10.1016/j.micinf2012.10.008>
LUDANDEKAR ET AL., NAT. REV. IMM., 2005, Retrieved from the Internet <URL:https://doi.org/10.1038/nril732>
MARIA ALIMOVA ET AL: "Summary", BIORXIV, 30 June 2020 (2020-06-30), XP055757822, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2020.06.30.180380v1.full.pdf> DOI: 10.1101/2020.06.30.180380 *
METHA ET AL., THE LANCET, vol. 395, 2020, pages 10229, Retrieved from the Internet <URL:https://doi.org/10.1016/S0140-6736(20)30628-0>
MOCSAI ET AL., NAT REV IMMUNOL., vol. 10, no. 6, 2010, pages 387 - 402
QI, BBRC, 2020, Retrieved from the Internet <URL:https://doi.Org/10.1016/j.bbrc.2020.03.044>
SAHA SOVAN ET AL: "Is Fostamatinib a possible drug for COVID-19? - A computational study", 1 May 2020 (2020-05-01), pages 1 - 28, XP055881001, Retrieved from the Internet <URL:https://www.researchgate.net/profile/Sovan-Saha-3/publication/341324097_Is_Fostamatinib_a_possible_drug_for_COVID-19_-_A_computational_study/links/5f3d572ca6fdcccc43d3a098/Is-Fostamatinib-a-possible-drug-for-COVID-19-A-computational-study.pdf> [retrieved on 20220119], DOI: 10.31219/osf.io/7hgpj *
SAITOH ET AL., CELL HOST MICROBE, vol. 12, no. 1, 2012, pages 109 - 16
SIDDIQI ET AL., J. HEART AND LUNG TRANS, 2020
STEBBING ET AL., LANCET INFECT DIS, 2020, Retrieved from the Internet <URL:https://doi.org/10.1016/S1473-3099(20)30232-2>
SUNGNAK ET AL., QBIO PREPRINT; ARXIV:2003.06122 [Q-BIO.CB
TACCONE ET AL., LANCET RESP. MED., 2020
ZHAO ET AL., BIORXV PREPRINT HTTPS://DOI.ORG/10.1101/2020.01.26.919985
ZHAO XIAOYU ET AL: "Activation of C-Type Lectin Receptor and (RIG)-I-Like Receptors Contributes to Proinflammatory Response in Middle East Respiratory Syndrome Coronavirus-Infected Macrophages", JOURNAL OF INFECTIOUS DISEASES, 28 September 2019 (2019-09-28), US, XP055882037, ISSN: 0022-1899, DOI: 10.1093/infdis/jiz483 *
ZHOU ET AL., LANCET, vol. 395, 2020, pages 1054 - 62, Retrieved from the Internet <URL:https://doi.org/10.1016/S0140-6736(20)30566-3>
ZOU ET AL., FRONT MED, 2020, Retrieved from the Internet <URL:https://doi.org/10.1007/sll684-020-0754-0>
ZOUQILU ET AL., NAT. REV. IMM., 2018, Retrieved from the Internet <URL:https://doi.org/10.1038/nri.2017.106>

Similar Documents

Publication Publication Date Title
WO2017202274A1 (fr) Dérivé d&#39;éther d&#39;alcool nicotinylique, procédé de préparation associé, composition pharmaceutique et ses utilisations
JP5898067B2 (ja) がん及び非新生物性状態の治療方法
US8927576B2 (en) HCV inhibitor and therapeutic agent combinations
AU2018237047A1 (en) Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
CA3064247A1 (fr) Inhibiteurs des janus kinases pour le traitement du syndrome de l&#39;oeil sec et autres maladies de l&#39;oeil
KR20210097124A (ko) 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
US20210163493A1 (en) Heteroaryl amide compounds as sting activators
WO2022072783A1 (fr) Composés diones bicycliques en tant qu&#39;inhibiteurs de kras
WO2019136244A1 (fr) Composés hétérocycliques pour le traitement d&#39;une prolifération cellulaire anormale
US20220064188A1 (en) Vinyl imidazole compounds as inhibitors of kras
WO2023049831A1 (fr) Traitement de cancers associés au papillomavirus humain par des inhibiteurs de pd-l1
JP2022541825A (ja) Ａｔｒキナーゼ阻害剤としての置換２－モルホリノピリジン誘導体
US20230122909A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
WO2023034290A1 (fr) Composés de naphtyridine en tant qu&#39;inhibiteurs de kras
WO2022063869A2 (fr) Composés pour le traitement d&#39;infections virales
CN115698014A (zh) 用于治疗医学病症的细胞周期蛋白依赖性激酶抑制化合物
CA2789750C (fr) Agoniste de recepteur de ghreline pour le traitement de la dyscrasie
US20210395258A1 (en) Heterocyclic derivatives as pi3k inhibitors
WO2022079250A1 (fr) Composés pour le traitement d&#39;infections virales
US20230226041A1 (en) Compounds for the treatment of viral infections
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
AU2021291358A1 (en) Compounds for the treatment of viral infections
US20230301991A1 (en) Compounds for the treatment of viral infections
RU2806857C2 (ru) Соединения, фармацевтические композиции, способы приготовления соединений и их применение в качестве ингибиторов киназы atr
CN116507335A (zh) 用于治疗病毒感染的atr抑制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21798303

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21798303

Country of ref document: EP

Kind code of ref document: A1